JAK Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis.

Publication Type:

Journal Article


Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2014)


2014, April 2014, Clinical Research Division


Myelofibrosis (MF) is a manifestation of several disorders of hematopoiesis collectively referred to as myeloproliferative neoplasms (MPN). Allogeneic hematopoietic stem cell transplantation (ASCT) is the only therapy with proven curative potential. However, most patients with MF are in the 6(th) or 7(th) decade of life, and only some of these patients have been considered suitable transplant candidates. The development of reduced intensity conditioning regimens with limited toxicity has allowed clinicians to offer ASCT to a growing number of older patients. The availability of Janus Kinase (JAK)1/2 inhibitors allows clinicians to provide symptom relief and improved quality of life of MF patients. These drugs may also impact the decision regarding in particular the timing of ASCT. Future studies need to address the role of JAK1/2 inhibitors in patients who are transplant candidates and determine their role before and, possibly, after transplantation. The identification of indications for the use of JAK1/2 inhibitors in the context of transplantation may lead to new therapeutic strategies for patients with MF.